New drug cocktail aims to shrink colon tumors before surgery
NCT ID NCT07156682
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tests whether a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus chemotherapy can shrink tumors before surgery in people with stage III colon cancer that is microsatellite stable (pMMR/MSS). About 21 participants will receive four cycles of the drug combo, then undergo surgery. The main goal is to see if the cancer disappears completely after treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
iparomlimab and tuvonralimab (QL1706) plus XELOX chemotherapy (oxaliplatin and capecitabine)
What this could lead to
If this works, it could lead to a new treatment option that shrinks tumors before surgery, potentially improving outcomes for people with hard-to-treat stage III colon cancer.
What could go wrong
This is a small, early-phase study with only 21 participants, so results may not apply to everyone. The combination therapy may cause significant side effects, and it is not yet known if it will improve long-term survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLON CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Qilu hospital of Shandong University
Jinan, Shandong, 250012, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact